Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company’s Phase 2a portion of the Phase 1/2a clinical trial of GALE-301, or Folate Binding Protein, will be presented at the upcoming European Society for Medical Oncology (ESMO) European Cancer Congress 2015 in Vienna, Austria. Details of the poster presentation are as follows:
|Abstract #:||2764 – the abstract can be found on the conference website here|
|Title:||Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients|
|to prevent recurrence|
|Session Title:||Gynaecological Cancer|
|Date:||Monday, September 28, 2015|
|Time:||9:15 a.m. to 11:15 a.m. local time|
|Location:||Hall C (Original Source)|
Shares of Galena Biopharma closed last Friday at $1.70. GALE has a 1-year high of $2.47 and a 1-year low of $1.10. The stock’s 50-day moving average is $1.55 and its 200-day moving average is $1.58.
On the ratings front, Galena Biopharma has been the subject of a number of recent research reports. In a report issued on August 7, MLV & Co. analyst Vernon Bernardino reiterated a Buy rating on GALE, with a price target of $5, which represents a potential upside of 194.1% from where the stock is currently trading. Separately, on the same day, Cantor Fitzgerald’s Mara Goldstein reiterated a Sell rating on the stock and has a price target of $2.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Mara Goldstein have a total average return of -13.4% and 8.8% respectively. Bernardino has a success rate of 24.7% and is ranked #3707 out of 3755 analysts, while Goldstein has a success rate of 50.5% and is ranked #546.
Galena Biopharma Inc, is abiopharmaceutical company focused on developing and commercializing targeted oncology therapeutics that address medical needs across the full spectrum of cancer care.